A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Lone Tree Medical Center
University of Colorado Hospital
Study ID
Protocol Number: 19-1132
More information available at ClinicalTrials.gov: NCT03989115
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers